What's Hot
View all perspectives
Richard Conway RichardPAConway
2 years 5 months ago
Dr Gossec et al. Multidomain indices show consistent benefit when applied to IL23i guselkumab COSMOS trial. I like MDA (because its simple and so am I) so showing that. But same benefits seen in DAPSA, PASDAS, mCPDAI, GRACE, PsARC. @RheumNow #EULAR2022 POS1038 https://t.co/EU2VHpEGc3
Richard Conway RichardPAConway
2 years 5 months ago
Characteristics assoc outcomes PsO/PsA/axSpA @pedrommcmachado @rheum_covid bDMARDS, NSAIDs assoc better outcomes. Usually culprits assoc worse outcomes (age, CVD etc), and also disease activity and steroids @RheumNow #EULAR2022 OP0249 https://t.co/siLdQVj2jb https://t.co/BmdwspDhsG
Janet Pope Janetbirdope
2 years 5 months ago
What drives residual pain improvement in #JAKi treated pts? Dunno but #Baricitinib and #Sarilimab showed better pain decrease vs placebo and #Adalimumab. #OP0052 showed both #Tofacitinib & Adalimumab reduced pain more than placebo in PsA & RA if in remission @RheumNow @eular_org
Richard Conway RichardPAConway
2 years 5 months ago
Mease et al. IL23i guselkumab on axial outcomes in PsA at 2 years in DISCOVER-2. Guselkumab improves BASDAI, mBASDAI, spinal pain, ASDAS to week 100. Still trying to get my head around this seeming to work for PsA spinal disease but not axSpA @RheumNow #EULAR2022 POS1037 https://t.co/LZgXEl6Ohl
Dr. John Cush RheumNow
2 years 5 months ago
Babies! Safety and Outcomes Data on Pregnancies
#EULAR2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones that caught my eye...
https://t.co/ulQIo2gdlO https://t.co/dpoMd5Wbah
Dr. John Cush RheumNow
2 years 5 months ago
Getting Real on PMR
Dr. David Liew talks polymyalgia rheumatica and how our understanding has evolved over the years. #EULAR2022
https://t.co/BCdOTzeOHx https://t.co/VO95uHaKxg
Dzifa Dey RheumtoBloom
2 years 5 months ago
Full circle. I met Prof D Isenberg at my first EULAR Congress 10 years ago. He welcomed a strangers request to come for Rheumatology training at UCLH with open arms. A kind, generous soul. My heart is full whenever we meet.❤️ https://t.co/yvwYyDKRD6
David Liew drdavidliew
2 years 5 months ago
Looks like I’m not the only one who doesn’t let the absence of synovitis stop me from sometimes treating high-risk clinically suspect arthralgias i.e. ‘very early early RA’
The truth comes out in anonymous surveys!
#EULAR2022 @RheumNow https://t.co/BqTLy4HBWR
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 5 months ago
A bit late but finally managed to get a proper Danish pastries on Day 3 in 🇩🇰🥳 #EULARpastrychallenge 🥐 #EULAR2022 https://t.co/PhmOd3ylzb
TheDaoIndex KDAO2011
2 years 5 months ago
Interesting stats - over 4400 #EULAR2022 tweets yesterday but only half that number today. #ConferenceFatigue @RheumNow https://t.co/HILdrb5Wkd
By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around! PAnd congrats to you virtual Rheums for mastering the multi-screen, multitask simultaneous consumption posters, tweets and oral abstract presentations.
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 5 months ago
#OP0279 #EULAR2022 Let's start with N=5! Promising new therapy CAR T-cell in #lupus. All patients were refractory to various therapies and had active nephritis. Post-treatment, all responded clinically and serologically! Need to go to RCT next @RheumNow https://t.co/RaTlVALQqn
Eric Dein ericdeinmd
2 years 5 months ago
Difficult to Treat RA (D2TRA): Jacob van Laar
#EULAR2022 Points to consider @RheumNow
1. Consider the diagnosis! Misdiagnosis or mimic?
2. U/s when in doubt
3. Caution in comorbidities (obesity, fm) which can overestimate inflamm markers, disease activity https://t.co/YT9NRv7EA0
Poster Hall